Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Berthold

Showing results (11-20 of 160) with videos related to

Pageof 16
Sort By:
Medical and Pediatric Oncology|May 24, 2003
FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastomaRuediger Spitz, Barbara Hero, Karen Ernestus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastomaRuediger Spitz, Barbara Hero, Thorsten Simon, et al.
Pediatric Blood & Cancer|April 1, 2005
Lacking immunocytological GD2 expression in neuroblastoma: report of 3 casesRoswitha Schumacher-Kuckelkorn, Barbara Hero, Karen Ernestus, et al.
Journal of Pediatric Hematology/Oncology|February 7, 2007
Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trialThorsten Simon, Alfred Längler, Frank Berthold, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 16, 2007
[Endocarditis due to Granulicatella adiacens]Ilona Schwede, Werner Handrick, Martin Henrichs, et al.
Journal of Pediatric Hematology/Oncology|December 14, 2004
New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN statusThorsten Simon, Rüdiger Spitz, Andreas Faldum, et al.
Cancer Letters|July 16, 2005
Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11qThorsten Simon, Rüdiger Spitz, Barbara Hero, et al.
Pediatric Blood & Cancer|September 27, 2021
Hypercalcemia is a frequent side effect of 13-cis-retinoic acid treatment in patients with high-risk neuroblastomaMarc Hoemberg, Ruth Schwenzfeur, Frank Berthold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcomeAndré Oberthuer, Barbara Hero, Rüdiger Spitz, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2008
The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97Matthias Schmidt, Thorsten Simon, Barbara Hero, et al.
Pageof 16

Showing results (11-20 of 160) with videos related to

Sort By:
Pageof 16
Medical and Pediatric Oncology|May 24, 2003
FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastomaRuediger Spitz, Barbara Hero, Karen Ernestus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastomaRuediger Spitz, Barbara Hero, Thorsten Simon, et al.
Pediatric Blood & Cancer|April 1, 2005
Lacking immunocytological GD2 expression in neuroblastoma: report of 3 casesRoswitha Schumacher-Kuckelkorn, Barbara Hero, Karen Ernestus, et al.
Journal of Pediatric Hematology/Oncology|February 7, 2007
Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trialThorsten Simon, Alfred Längler, Frank Berthold, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 16, 2007
[Endocarditis due to Granulicatella adiacens]Ilona Schwede, Werner Handrick, Martin Henrichs, et al.
Journal of Pediatric Hematology/Oncology|December 14, 2004
New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN statusThorsten Simon, Rüdiger Spitz, Andreas Faldum, et al.
Cancer Letters|July 16, 2005
Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11qThorsten Simon, Rüdiger Spitz, Barbara Hero, et al.
Pediatric Blood & Cancer|September 27, 2021
Hypercalcemia is a frequent side effect of 13-cis-retinoic acid treatment in patients with high-risk neuroblastomaMarc Hoemberg, Ruth Schwenzfeur, Frank Berthold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcomeAndré Oberthuer, Barbara Hero, Rüdiger Spitz, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2008
The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97Matthias Schmidt, Thorsten Simon, Barbara Hero, et al.
Pageof 16